Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Kaspar, US
Brian Kaspar, San Diego, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090202490 | MUTANT ADENO-ASSOCIATED VIRUS VIRIONS AND METHODS OF USE THEREOF - The present invention provides mutant adeno-associated virus (AAV) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant AAV comprising one or more mutations in a capsid gene. The present invention further provides methods of generating the mutant AAV and mutant AAV libraries, and compositions comprising the mutant AAV. The present invention further provides recombinant AAV (rAAV) virions that comprise a mutant capsid protein. The present invention further provides nucleic acids comprising nucleotide sequences that encode mutant capsid proteins, and host cells comprising the nucleic acids. The present invention further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof. | 08-13-2009 |
Brian K. Kaspar, Westerville, OH US
| Patent application number | Description | Published |
|---|---|---|
| 20100178348 | Myostatin Inhibition for Enhancing Muscle and/or Improving Muscle Function - The present invention relates to methods for inhibiting myostatin, a regulator of muscle mass, for muscle enhancement (including inducing hypertrophy and/or hyperplasia) as well as improving muscle function (including decreasing atrophy and/or increasing endurance, force and/or strength). The methods involve delivering genes to cells using gene delivery in order to inhibit myostatin. Examples of genes to be delivered are genes encoding’ proteins such as Follistatin, Follistatin-related gene-1 (FLRG-I), growth differentiation factor associated protein-1 (GASP-I) and myostatin precursor propeptide. The genes are delivered using a recombinant Adeno-associated virus (rAAV) lacking rep and cap DNA capable of infecting the cells. Following introduction, the genes are expressed in the cell body of the infected cell and the encoded proteins are secreted systemically. In other methods-of the invention expression of proteins such as activin lib and myostatin is inhibited by oligonucleotide techniques to effect muscle enhancement. All the methods have applications in the treatment of musculoskeletal and neurodegenerative disorders among others, as well as enhancing muscle in livestock. | 07-15-2010 |
Derick L. Kaspar, Webster Groves, MO US
| Patent application number | Description | Published |
|---|---|---|
| 20110065959 | Removal of Silica from Water Soluble Compounds by Nanofiltration and Reverse Phase Chromatography - A process for separating soluble silica species such as monomeric silicic acid (or monosilicic acid) and low molecular weight soluble polymeric silica from impure water soluble compounds by membrane nanofiltration is provided. A process for separating soluble silica species and colloidal silica from impure water soluble compounds by reverse phase liquid chromatography is also provided. | 03-17-2011 |
Don Kaspar, Shiner, TX US
| Patent application number | Description | Published |
|---|---|---|
| 20100319127 | FOLDING FOOT PROTECTION DEVICE FOR A BEDDED PATIENT - An electrocoagulation reactor for the treatment of wastewater. The electrocoagulation reactor typically engages a DC power source and a source of wastewater to be treated. It has a housing with walls and a wastewater inlet, and a treated wastewater outlet. There is at least one anode/cathode pair of oppositely charged spaced apart plates that engage the power source to charge the anode with a positive charge and the cathode with a negative charge. Between each anode/cathode pair is at least one segmented intermediate plate, which is not engaged to the power source of electrical energy, and which intermediate plate is segmented into multiple segments, which multiple segments lay generally in the same plane. | 12-23-2010 |
Douglas Kaspar, Shiner, TX US
| Patent application number | Description | Published |
|---|---|---|
| 20110290667 | ELECTROCOAGULATION REACTOR HAVING SEGMENTED INTERMEDIATE UNCHARGED PLATES - An electrocoagulation reactor for the treatment of wastewater. The electrocoagulation reactor typically engages a DC power source and a source of wastewater to be treated. It has a housing with walls and a wastewater inlet, and a treated wastewater outlet. There is at least one anode/cathode pair of oppositely charged spaced apart plates that engage the power source to charge the anode with a positive charge and the cathode with a negative charge. Between each anode/cathode pair is at least one segmented intermediate plate, which is not engaged to the power source of electrical energy, and which intermediate plate is segmented into multiple segments, which multiple segments lay generally in the same plane. | 12-01-2011 |
Kala Marie Kaspar, St. Louis Park, MN US
| Patent application number | Description | Published |
|---|---|---|
| 20090148545 | METHODS OF USE AND NUTRITIONAL COMPOSITIONS OF TOUCHI EXTRACT - Disclosed is a method and composition for nutritional compositions containing -glucosidase inhibitors, and more specifically Touchi Extract and its uses in the treatment of many disorders. These disorders include diabetes, hyperlipidemia, obesity, Metabolic syndrome/Syndrome X, COPD, malabsorption, Crohn's disease, diarrhea, constipation, irritable bowel syndrome, human immunodeficiency virus, cystic fibrosis, non-alcoholic steatohepatitis, polycystic ovarian syndrome including associate infertility, and erectile dysfunction. Further, -glucosidase inhibitors, and more specifically Touchi Extract can be used to aid healing in critical care patients and for general wound healing. Additionally, -glucosidase inhibitors, including Touchi Extract can be used to enhance athletic performance. | 06-11-2009 |
| 20090291877 | TREATMENTS USING CITRULLINE - The invention provides a method and formulation for the treatment or maintenance of conditions that would be benefited from increasing or maintaining Arginine levels in the blood, and having improved taste characteristics over current Arginine supplementations. Further, this maintenance of Arginine levels in the blood will be beneficial in acute and chronic diseases with an impaired arginine to citrulline production rate. Further the invention provides a method for treating at least one of satiety and dyspepsia in an individual. In one embodiment, the method includes administering to an individual an effective amount of L-citrulline. | 11-26-2009 |
Roger L. Kaspar, Santa Cruz, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090170794 | Small interfering rnas that efficiently inhibit viral expression and methods of use thereof - The invention provides methods, compositions, and kits comprising small interfering RNA (shRNA or siRNA) which are useful for inhibition of viralmediated gene expression. Small interfering RNAs as described herein may be used in methods of treatment of HCV infection. ShRNA and siRNA constructs that target the internal ribosome entry site (IRES) sequence of HCV are described. | 07-02-2009 |
| 20110269816 | Inhibition of Viral Gene Expression Using Small Interfering RNA - The invention provides methods, compositions, and kits comprising small interfering RNA (shRNA or siRNA) that are useful for inhibition of viral-mediated gene expression. Small interfering RNAs as described herein can be used in methods of treatment of HCV infection. ShRNA and siRNA constructs targetING the internal ribosome entry site (IRES) sequence of HCV are described. | 11-03-2011 |
Roger L. Kaspar, Santa Crus, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090043279 | MICRONEEDLE ARRAYS FORMED FROM POLYMER FILMS - The present invention provides for transdermal delivery devices having microneedle arrays, as well as methods for their manufacture and use. In one embodiment, a transdermal delivery device is provided. The transdermal delivery device includes a polymer layer which has microneedles projecting from one of its surfaces. The microneedles are compositionally homogenous with the polymer base layer. | 02-12-2009 |
Roger Louis Kaspar, Santa Cruz, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20080207672 | Methods of treating keratin hyperproliferation disorders using mTOR inhibitors - A method of treating or preventing keratin hyperproliferation skin disorders is set forth. The method includes the administration of an mTOR inhibitor to a subject afflicted with the hyperproliferation disorder. The mTOR inhibitor can be administered to the subject via any means known in the art including oral, topical, and transdermal administration. | 08-28-2008 |
| 20090181908 | METHODS AND COMPOSITIONS FOR TREATING KERATIN HYPERPROLIFERATIVE DISORDERS - A method for keratin hyperproliferation disorders such as corns, calluses, or keratosis pilaris (KP) by administering to a subject experiencing the disorder a therapeutically effective amount of an RNA sequence which inhibits expression of a gene encoding for a keratin selected from the group consisting of K6a, K6b, K16, K17, and combinations thereof. | 07-16-2009 |